PubRank

Sven T Pleger

Author PubWeight™ 29.77‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008 3.46
2 Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res 2006 2.07
3 Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation 2006 1.73
4 S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes. J Am Coll Cardiol 2011 1.68
5 Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation 2006 1.64
6 Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest 2004 1.58
7 Transgenic overexpression of the Ca2+-binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance. J Biol Chem 2003 1.43
8 Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer 2010 1.38
9 Extracellular S100A1 protein inhibits apoptosis in ventricular cardiomyocytes via activation of the extracellular signal-regulated protein kinase 1/2 (ERK1/2). J Biol Chem 2003 1.25
10 S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy. J Mol Cell Cardiol 2009 1.13
11 The C terminus (amino acids 75-94) and the linker region (amino acids 42-54) of the Ca2+-binding protein S100A1 differentially enhance sarcoplasmic Ca2+ release in murine skinned skeletal muscle fibers. J Biol Chem 2003 1.11
12 S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance. Am J Physiol Regul Integr Comp Physiol 2007 1.08
13 HMGB1: the missing link between diabetes mellitus and heart failure. Basic Res Cardiol 2010 0.98
14 Incidence of late occurring bradyarrhythmias after TAVI with the self-expanding CoreValve(®) aortic bioprosthesis. Clin Res Cardiol 2011 0.96
15 S100A1 gene transfer: a strategy to strengthen engineered cardiac grafts. J Gene Med 2004 0.91
16 Feasibility and clinical benefit of a suture-mediated closure device for femoral vein access after percutaneous edge-to-edge mitral valve repair. EuroIntervention 2015 0.88
17 S100A1 deficiency impairs postischemic angiogenesis via compromised proangiogenic endothelial cell function and nitric oxide synthase regulation. Circ Res 2012 0.87
18 Preserved prognostic value of preinterventional troponin T levels despite successful TAVI in patients with severe aortic stenosis. Clin Res Cardiol 2013 0.82
19 S100 proteins: a missing piece in the puzzle of heart failure? Cardiovasc Res 2007 0.80
20 C-reactive protein kinetics and its prognostic value after transfemoral aortic valve implantation. J Invasive Cardiol 2012 0.80
21 The extent of aortic annulus calcification is a predictor of postprocedural eccentricity and paravalvular regurgitation: a pre- and postinterventional cardiac computed tomography angiography study. J Invasive Cardiol 2015 0.79
22 Percutaneous and surgical treatment of mitral valve regurgitation. Dtsch Arztebl Int 2011 0.79
23 The yin and yang of increased beta-adrenergic signaling: beta1-adrenergic genetic polymorphism and protection against acute myocardial ischemic injury. Am J Physiol Heart Circ Physiol 2006 0.78
24 Feasibility of sheathless transfemoral aortic valve implantation in patients with small access vessel diameters. Clin Res Cardiol 2014 0.77
25 First experience with the new generation Edwards Sapien 3 aortic bioprosthesis: procedural results and short term outcome. J Interv Cardiol 2015 0.77
26 S100A1 gene therapy in small and large animals. Methods Mol Biol 2013 0.77
27 Using the GORE® Septal Occluder (GSO) in challenging patent foramen ovale (PFO) anatomies. J Interv Cardiol 2015 0.77
28 The Effects of Mitral Valve Repair on Memory Performance, Executive Function, and Psychological Measures in Patients With Heart Failure. Psychosom Med 2016 0.76
29 Translational medicine in genetic familial diseases: from the autopsy room to the molecular bench and vice versa. Hum Pathol 2005 0.75
30 Procedural results with the self-expanding 31 mm CoreValve aortic bioprosthesis in patients with large annuli. J Interv Cardiol 2014 0.75
31 Feasibility and safety of vitamin K antagonist monotherapy in atrial fibrillation patients undergoing transcatheter aortic valve implantation. EuroIntervention 2017 0.75
32 Recent findings into the potential of gene therapy to reverse heart failure. Expert Opin Biol Ther 2007 0.75
33 Hope for a broken heart? Trends Biotechnol 2004 0.75
34 Improved procedural results after CoreValve implantation with the new AccuTrak delivery system. J Interv Cardiol 2012 0.75